The purpose of this program is to conduct a practice-based, randomized clinical trial of antihypertensive pharmacologic treatment and, in a specific subset, lipid-lowering, in 40,000 high-risk hypertensive patients including at least 55% African-Americans. The purpose of the antihypertensive trial is to determine whether the combined incidence of fatal coronary heart disease (CHD)) and non-fatal myocardial infarction differs between diuretic treatment and three alternative antihypertensive pharmacologic treatments: a calcium antagonist, an angiotensin converting enzyme (ACL) inhibitor, and an alpha adrenergic blocker. The purpose of the cholesterol-lowering component is to determine whether lowering serum cholesterol in moderately hypercholesterolemic men and women aged 60 years and older with a 3-hydroxymethylgiutaryl coenzyme A (HMG CoA) reductase inhibitor will reduce the combined incidence of fatal CHD and non-fatal myocardial infarction. Inclusion of the cholesterol- lowering component is contingent on obtaining an HMG-CoA reductase inhibitor, which has not been finalized at this time. Approval to proceed with the lipid-lowering trial will not be granted until the availability of this agent has been secured. Rather than using independently funded clinics, patients will be recruited through office-based practices and hypertension clinics which will be reimbursed by the Clinical Trials Center (CTC) on a per-patient basis. This contract is for the Clinical Trials Center. Some of the functions of the Clinical Trials Center include coordinating all data collection, storage of data, analysis activities related to the study, and recruiting and training (along with the NHLBI) appropriate clinical sites and core laboratories required to conduct the study.

Project Start
1993-08-02
Project End
2002-07-31
Budget Start
1994-09-28
Budget End
1995-04-14
Support Year
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Texas Health Science Center Houston
Department
Biostatistics & Other Math Sci
Type
Schools of Public Health
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77225
Dewland, Thomas A; Soliman, Elsayed Z; Yamal, Jose-Miguel et al. (2017) Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Circ Arrhythm Electrophysiol 10:
Haywood, L Julian; Davis, Barry R; Piller, Linda B et al. (2017) Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. J Natl Med Assoc 109:172-181
Whittle, Jeff; Lynch, Amy I; Tanner, Rikki M et al. (2016) Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. Clin J Am Soc Nephrol 11:471-80
Kronish, Ian M; Lynch, Amy I; Oparil, Suzanne et al. (2016) The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension 68:39-45
Alderman, Michael H; Davis, Barry R; Piller, Linda B et al. (2016) Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]). Am J Cardiol 117:105-15
Einhorn, Paula T; Whelton, Paul K; Davis, Barry R et al. (2015) Real-world evidence supports optimally dosed thiazide-type diuretics as preferred in treatment regimens of older adults with hypertension. J Am Geriatr Soc 63:1045-7
Muntner, Paul; Whittle, Jeff; Lynch, Amy I et al. (2015) Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med 163:329-38
Muntner, Paul; Levitan, Emily B; Lynch, Amy I et al. (2014) Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich) 16:323-30
Piller, Linda B; Simpson, Lara M; Baraniuk, Sarah et al. (2014) Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT. J Gen Intern Med 29:1475-83
Sørensen, Izel F; Vazquez, Ana I; Irvin, Marguerite R et al. (2014) Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study. Pharmacogenet Genomics 24:556-63

Showing the most recent 10 out of 69 publications